Treatment of carcinoid syndrome

2000273 citationsJournal Article

Authors

Dermot O’Toole · Hôpital Beaujon

Michel Ducreux · Institut Gustave Roussy

Gilles Bommelaer · Hôtel-Dieu de Lyon

Jean-Louis Wémeau · Hôpital Claude Huriez

Olivier Bouch� · Hôpital Laennec

F. Catus · Ipsen (France)

Jo�lle Blumberg ·

Abstract

Lanreotide and octreotide are equally efficacious in terms of symptom control and reduction in tumor cell markers for patients with carcinoid syndrome. Due to its simplified mode of administration, most patients prefer treatment with lanreotide.

Topics & Keywords

Neuroendocrine Tumor Research Advances Pituitary Gland Disorders and Treatments Myasthenia Gravis and Thymoma

Publication Details

Published in: Cancer

Volume 88, Issue 4, pp. 770-776

DOI: 10.1002/(sici)1097-0142(20000215)88:4<770::aid-cncr6>3.0.co;2-0

Field-Weighted Citation Impact: 5.23

Command Palette

Treatment of carcinoid syndrome

Authors

Abstract

Topics & Keywords

Publication Details